Biomarker ID | 282 |
PMID | 18543251 |
Year | 2008 |
Biomarker | Golgi phosphoprotein 2 (GOLPH2) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-TGF-beta regulation of extracellular matrix |
Experiment | prostate cancer Vs normal prostate epithelium |
Type of Biomarker | Diagnostic |
Cohort | A tissue microarray (TMA) containing 320 paired normal and prostate cancer TMA spots from 40 patients |
Senstivity | 8190% |
Specificity | 7560% |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | Immunohistochemical |
Clinical | No |
Remarks | Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis. |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Dataset |
Technical Name | GOLM1 |